OR WAIT null SECS
© 2022 MJH Life Sciences and BioPharm International. All rights reserved.
© 2022 MJH Life Sciences™ and BioPharm International. All rights reserved.
January 18, 2022
Samsung Biologics is planning to construct a new manufacturing facility in Incheon, South Korea, that will offer multi-product manufacturing, including cell and gene therapies and next-gen vaccines.
January 13, 2022
The collaboration between Bristol Myers Squibb and Century Therapeutics will combine Century’s iPSC-derived allogeneic cell therapy platform with Bristol Myers Squibb’s expertise in cell therapy and oncology drug development.
January 02, 2022
Enhancement of resin technology can improve the ability of chromatography to purify the growing landscape of increasingly complex biomolecules.
December 13, 2021
SKAN’s new Cellana isolator is designed for GMP manufacturing of ATMPs.
December 09, 2021
Leucid Bio will collaborate with Lonza to use Lonza’s Cocoon Platform for clinical and commercial manufacturing of CAR T cells for Leucid’s lead candidate.
December 02, 2021
Timing is everything, and it might be ideal for acceleration of real-time monitoring solutions.
Autologous tumor cells engineered for immune system stimulation can target unique metabolic, genomic, and phenotypic characteristics of cancer cells.
November 19, 2021
Scientific innovation and regulatory reformations are helping to drive the global biopharma market forward, but a balance between cost and value still needs to be accepted for widespread adoption.
November 10, 2021
Part 2—Industry experts from MilliporeSigma, Lonza, Astrea Bioseparations, and Sartorius provide insight and examples about solving critical challenges in both analytics and process development for emerging therapies.
November 08, 2021
Part 1—Industry experts from MilliporeSigma, Lonza, Astrea Bioseparations, and Sartorius discuss key issues affecting the development of emerging biotherapies.